Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that blood samples from donors on teratogenic drugs sometimes exceeded recommended concentration limits, suggesting a need for improved deferral policies.

This review indicates that many former FDA category D and X systemic dermatologic medications may negatively impact male fertility, with further research needed to assess potential teratogenic effects.

In this study, twice daily application of 3 μg/g calcitriol ointment was reported to be safe, effective, and well tolerated for treating moderate to severe chronic plaque psoriasis on the face and surrounding areas.

This source highlights that topical retinoids, particularly adapalene and its combinations, are crucial in treating acne due to their rapid action, sustained effects, and good tolerability; the study underscores the enhanced patient adherence with Deriva C MS gel for acne treatment.

This review discusses the use of acitretin, a retinoid approved since 1997, for various forms of psoriasis and its potential benefits in combination therapy, but reports no new clinical findings.

This source reports that clascoterone cream has been approved in the U.S. for treating acne vulgaris in patients aged 12 and older, suggesting it works by competing with dihydrotestosterone at androgen receptors to mitigate acne's effects.

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.

This source describes clascoterone, a new topical treatment for acne vulgaris that blocks androgen receptors to reduce sebaceous gland activity and inflammation, offering a lower risk of systemic side effects compared to oral treatments.

This article reviews the development milestones of clascoterone up to its first approval for treating acne vulgaris, reporting no new clinical results for androgenetic alopecia.

This case study highlights a pediatric instance of eruptive vellus hair cysts partially responding to calcipotriene cream, aiming to remind clinicians about this often overlooked condition.

This study reported that dermatological adverse events are common in patients treated with amivantamab for non-small cell lung cancer, often impacting quality of life and requiring treatment modifications.

In this case report, a 48-year-old woman with refractory discoid lupus erythematosus showed significant improvement, including hair regrowth, after treatment with deucravacitinib, suggesting its potential as an effective therapy for this condition.

In this case series, treatment with clascoterone cream 1% was reported to be effective and well tolerated for diverse acne vulgaris patients, improving clinical outcomes whether used alone or in combination with other therapies, and addressing various other skin conditions.

This review highlights that deucravacitinib, a selective TYK2 inhibitor, shows promise as an effective treatment for psoriasis and other inflammatory skin diseases, though real-world evidence beyond psoriasis is still emerging.

This review discusses current treatments for discoid lupus erythematosus and highlights anifrolumab as a promising option for difficult cases, but no new clinical results are reported.

In this case report, a female patient with both psoriasis and lichen planus initially responded to acitretin and topical mometasone but experienced a relapse after stopping the treatment. The authors reported marked improvement within 3 months after switching to upadacitinib, aiming to guide clinical decision-making.

This study found that applying BPM 31543 twice daily was safe, well-tolerated, and showed signs of reducing chemotherapy-induced alopecia in women receiving taxane-based chemotherapy.

This study found that the retinoic acid derivative Ro 10-9359 cleared psoriasis lesions in over half of the patients, but most experienced side effects, including skin issues and altered liver enzyme levels.

This case report describes repigmentation and curling of hair in a patient undergoing acitretin therapy.

This study concluded that the topical gel VB1953 reduced inflammatory and non-inflammatory acne lesions and resistant bacteria in patients with clindamycin-resistant acne, showing promise as an effective treatment.

This research found that combining a 308-nm excimer laser with oral compound glycyrrhizin and topical 0.03% tacrolimus was more effective for treating pediatric facial and cervical vitiligo, resulting in faster and higher rates of repigmentation with minimal adverse effects compared to glycyrrhizin and tacrolimus alone.

This study found that topical BPM31543 was safe, tolerable, and showed potential to reduce chemotherapy-induced alopecia at higher dosing levels among adult women with cancer receiving taxane-based chemotherapy.

In this article, the authors reported that calcipotriol/betamethasone dipropionate aerosol foam significantly improved scalp psoriasis symptoms in three patients by reducing itching and improving flaky patches within a four-week treatment period, confirming its efficacy and enhanced skin penetration compared to older formulations.

In this study involving women undergoing taxane-based chemotherapy, a twice-daily topical application of BPM31543 was well-tolerated and showed potential in reducing severe hair loss, prompting further investigation at higher doses.

In this case study, calcitriol treatment led to improvement in scleroderma symptoms and partial hair regrowth in a 20-year-old girl after other treatments had failed.

This study found that calcipotriol scalp solution was more effective than a coal tar-based shampoo for treating mild to moderate scalp psoriasis and showed continued efficacy with long-term use.

This study found that among patients with folliculitis decalvans, treatment with isotretinoin achieved the highest rate of stable remission compared to antibiotic regimens like clindamycin and rifampicin.